Proponents of cannabis use in a medical context have often suggested that it is a superior substitute of opioid for chronic pain management. Cannabis owes its analgesic properties to components called cannabinoids, with the two most prominent being cannabidiol (CBD) and tetrahydrocannabinol (THC). Both compounds have similar potential for treating chronic pain, however, while THC is addictive, CBD is not and therefore is of special clinical interest.
These compounds exert biological effects by binding and activating cannabinoid receptors in our bodies.
Two main subtypes of these receptors are type 1 (CB1), which are primarily located in the brain and type 2 (CB2), which are primarily located in the immune system. Therefore, several studies have suggested that cannabis can reduce both neuropathic pain, which is caused by damage or diseases affecting the somatosensory nervous system, by acting on CB1 and inflammatory pain, which is the hypersensitivity to pain caused by inflammation, by acting on CB2. However, the results of some of these studies lack statistical significance and findings from different studies are sometimes inconsistent. In addition, there also exists significant evidence of adverse side effects associated with cannabinoids treatment. For the above reasons, additional clinical research needs to be conducted before definite conclusions on the pain-relieving properties and medical application of cannabis can be reached.
EMPLOYER Empowering Cancer Patients and their Caregivers: CSC Partners with EO Care for Clinically Guided Cannabis Support
Cancer Support Community (CSC) has teamed up with EO Care, a leader in clinically guided cannabis health solutions, to provide cancer patients, survivors, and their caregivers with comprehensive support.
Rescheduling Cannabis to a Schedule III Controlled Substance: A Regulator’s Perspective
Recently, the Department of Health and Human Services recommended that cannabis be reclassified from a Schedule I Controlled Substance to a Schedule III Controlled Substance under the federal Controlled Substances Act. In a PM360 article Rescheduling Cannabis to a Schedule III Controlled Substance: A Regulator’s Perspective,
Insight for Employers: Employees Are More Likely to Apply for Jobs Offering Cannabis Benefits
As more states legalize the use of cannabis, it can be challenging for employers to keep up and find reliable information. A recent Benefits Pro article, Employees are more likely to apply for jobs that offer cannabis benefits, shares findings from an EO Care ...